JP2017518304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518304A5 JP2017518304A5 JP2016570835A JP2016570835A JP2017518304A5 JP 2017518304 A5 JP2017518304 A5 JP 2017518304A5 JP 2016570835 A JP2016570835 A JP 2016570835A JP 2016570835 A JP2016570835 A JP 2016570835A JP 2017518304 A5 JP2017518304 A5 JP 2017518304A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- conjugate
- antibody
- formula
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 37
- 239000000562 conjugate Substances 0.000 claims 26
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 12
- 235000018417 cysteine Nutrition 0.000 claims 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 108010044540 auristatin Proteins 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 2
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims 2
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 claims 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 2
- 230000000975 bioactive effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000000611 antibody drug conjugate Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 0 CCC(C*(C)(C)C*C)C(NC)=O Chemical compound CCC(C*(C)(C)C*C)C(NC)=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462006816P | 2014-06-02 | 2014-06-02 | |
| US62/006,816 | 2014-06-02 | ||
| US201562139052P | 2015-03-27 | 2015-03-27 | |
| US62/139,052 | 2015-03-27 | ||
| PCT/US2015/033618 WO2015187596A2 (en) | 2014-06-02 | 2015-06-01 | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017518304A JP2017518304A (ja) | 2017-07-06 |
| JP2017518304A5 true JP2017518304A5 (cg-RX-API-DMAC7.html) | 2018-07-05 |
| JP6800021B2 JP6800021B2 (ja) | 2020-12-16 |
Family
ID=54767553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570835A Active JP6800021B2 (ja) | 2014-06-02 | 2015-06-01 | 抗体−薬物コンジュゲート、それらの製造、及びそれらの治療用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9951141B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3148592A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6800021B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106573074B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2950155C (cg-RX-API-DMAC7.html) |
| HK (1) | HK1231367A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015187596A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201704846VA (en) | 2012-03-14 | 2017-07-28 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| TW201920283A (zh) | 2012-12-24 | 2019-06-01 | 美商艾伯維有限公司 | 催乳激素受體結合蛋白質及其用途 |
| KR102306490B1 (ko) | 2013-03-15 | 2021-09-28 | 리제너론 파아마슈티컬스, 인크. | 생물학적 활성 분자, 그의 접합체 및 치료 용도 |
| EP3038624B1 (en) | 2013-08-26 | 2024-09-25 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
| EP3148592A2 (en) * | 2014-06-02 | 2017-04-05 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
| CA2954934C (en) | 2014-06-30 | 2023-09-26 | Glykos Finland Oy | Drug derivative and conjugates |
| SG11201707148PA (en) | 2015-03-27 | 2017-10-30 | Regeneron Pharma | Maytansinoid derivatives, conjugates thereof, and methods of use |
| CN118743763A (zh) * | 2015-08-14 | 2024-10-08 | 荣昌生物制药(烟台)股份有限公司 | 抗体-药物偶联物的共价连接子及其制备方法与应用 |
| PH12018501589B1 (en) | 2016-01-25 | 2022-08-10 | Regeneron Pharma | Maytansinoid derivatives, conjugates thereof, and methods of use |
| EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| CN109641051A (zh) | 2016-06-17 | 2019-04-16 | 美真达治疗公司 | 用于耗尽细胞的组合物和方法 |
| KR102725761B1 (ko) | 2017-01-20 | 2024-11-04 | 하이델베르크 파마 리서치 게엠베하 | Cd137+ 세포의 고갈을 위한 조성물 및 방법 |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗-prlr抗體藥物軛合物(adc)及其用途 |
| WO2019089962A1 (en) | 2017-11-03 | 2019-05-09 | Osteoanalgesia, Llc | Drug delivery system for treating disease |
| CA3080857A1 (en) * | 2017-11-07 | 2019-05-16 | Regeneron Pharmaceuticals, Inc. | Hydrophilic linkers for antibody drug conjugates |
| BR112020016005A2 (pt) | 2018-02-07 | 2020-12-15 | Regeneron Pharmaceuticals, Inc. | Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio |
| CN118955710A (zh) | 2018-05-09 | 2024-11-15 | 里珍纳龙药品有限公司 | 抗msr1抗体及其使用方法 |
| US11448651B2 (en) * | 2018-07-10 | 2022-09-20 | Regeneron Pharmaceuticals, Inc. | Modifying binding molecules to minimize pre-exisiting interactions |
| US11666658B2 (en) | 2018-12-21 | 2023-06-06 | Regeneran Pharmaceuticals, Inc. | Rifamycin analogs and antibody-drug conjugates thereof |
| JP2022523854A (ja) * | 2019-03-07 | 2022-04-26 | エービーエル バイオ インコーポレイテッド | 抗体-薬物コンジュゲート及びその用途 |
| TWI862645B (zh) | 2019-07-27 | 2024-11-21 | 美商布里生物科學股份有限公司 | 腺苷衍生物及包含其之醫藥組合物 |
| JP7252333B2 (ja) | 2019-09-29 | 2023-04-04 | 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 | 酸法による抗体薬物複合体中間体の調製方法及びその応用 |
| CN113171470B (zh) * | 2020-01-24 | 2024-06-04 | 香港科技大学 | 聚集诱导发光分子—噬菌体生物偶联物 |
| IL319200A (en) | 2020-04-16 | 2025-04-01 | Regeneron Pharma | Antibody-drug conjugates prepared using Diels-Alder compression methods |
| WO2022015656A1 (en) | 2020-07-13 | 2022-01-20 | Regeneron Pharmaceuticals, Inc. | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
| MX2023002974A (es) | 2020-09-14 | 2023-05-25 | Regeneron Pharma | Conjugados de anticuerpo-farmaco que comprenden peptidomimeticos glp1 y usos de los mismos. |
| CN112285361B (zh) * | 2020-09-27 | 2023-12-05 | 中国人民解放军空军军医大学 | 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂 |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| EP4281083A4 (en) | 2021-01-25 | 2025-01-01 | Brii Biosciences, Inc. | COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS |
| MX2023008004A (es) | 2021-01-25 | 2023-07-13 | Brii Biosciences Inc | Derivado de adenosina y composicion farmaceutica que lo comprende. |
| CN118829449A (zh) | 2022-01-12 | 2024-10-22 | 瑞泽恩制药公司 | 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途 |
| CA3243669A1 (en) | 2022-03-11 | 2023-09-14 | Regeneron Pharmaceuticals, Inc. | ANTI-GLP1R ANTIBODY-DRUG CONJUGATES INCLUDING GLP1 PEPTIDOMIMETS AND THEIR USES |
| CN114894911B (zh) * | 2022-03-18 | 2023-10-24 | 辽宁成大生物股份有限公司 | 一种控制牛血清产品质量方法 |
| US20240053333A1 (en) | 2022-08-03 | 2024-02-15 | Nautilus Subsidiary, Inc. | Chemical modification of antibodies and functional fragments thereof |
| US20240269308A1 (en) | 2022-12-21 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof |
| WO2025096921A1 (en) | 2023-11-03 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Peptide acids as a glp1r agonist and antibody-drug conjugates thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| KR101531400B1 (ko) | 2003-06-27 | 2015-06-26 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도 |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
| EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| FR2974741B1 (fr) | 2011-05-06 | 2013-06-28 | Francis Poizot | Dispositif de production de mousse |
| SG11201402686UA (en) | 2011-12-05 | 2014-06-27 | Igenica Inc | Antibody-drug conjugates and related compounds, compositions, and methods |
| GB201210770D0 (en) | 2012-06-18 | 2012-08-01 | Polytherics Ltd | Novel conjugation reagents |
| IN2014DN10428A (cg-RX-API-DMAC7.html) * | 2012-06-19 | 2015-08-21 | Polytherics Ltd | |
| NO2789793T3 (cg-RX-API-DMAC7.html) | 2012-10-24 | 2018-01-27 | ||
| KR102306490B1 (ko) | 2013-03-15 | 2021-09-28 | 리제너론 파아마슈티컬스, 인크. | 생물학적 활성 분자, 그의 접합체 및 치료 용도 |
| NZ714765A (en) | 2013-06-06 | 2021-12-24 | Pf Medicament | Anti-c10orf54 antibodies and uses thereof |
| WO2014197854A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
| WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| WO2014197871A2 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates, compositions and methods of use |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
| EP3148592A2 (en) * | 2014-06-02 | 2017-04-05 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
-
2015
- 2015-06-01 EP EP15738502.2A patent/EP3148592A2/en active Pending
- 2015-06-01 JP JP2016570835A patent/JP6800021B2/ja active Active
- 2015-06-01 WO PCT/US2015/033618 patent/WO2015187596A2/en not_active Ceased
- 2015-06-01 HK HK17104688.0A patent/HK1231367A1/zh unknown
- 2015-06-01 CA CA2950155A patent/CA2950155C/en active Active
- 2015-06-01 US US15/314,909 patent/US9951141B2/en active Active
- 2015-06-01 CN CN201580029530.1A patent/CN106573074B/zh active Active
-
2018
- 2018-03-20 US US15/926,998 patent/US10752690B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017518304A5 (cg-RX-API-DMAC7.html) | ||
| JP2024541059A (ja) | Bcmaモノクローナル抗体及び抗体薬物複合体 | |
| AU2015273098B2 (en) | Auristatin derivatives and conjugates thereof | |
| RU2016139340A (ru) | Коньюгаты "антитело - лекарственное средство" с высокой лекарственной нагрузкой | |
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| HRP20231609T1 (hr) | Konjugati lijeka koji sadrže antitijela protiv klaudina 18.2 | |
| JP2017537893A5 (cg-RX-API-DMAC7.html) | ||
| JP2016523810A5 (cg-RX-API-DMAC7.html) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| JP2013505944A5 (cg-RX-API-DMAC7.html) | ||
| JP2018505146A5 (cg-RX-API-DMAC7.html) | ||
| RU2014124984A (ru) | Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы | |
| JP6957629B2 (ja) | 非線状自壊性リンカーおよびそのコンジュゲート | |
| JP2016508136A5 (cg-RX-API-DMAC7.html) | ||
| RU2015119561A (ru) | Новые конъюгаты лекарственное вещество-белок | |
| JP2011500725A5 (cg-RX-API-DMAC7.html) | ||
| JP2017525755A5 (cg-RX-API-DMAC7.html) | ||
| RU2016130933A (ru) | Сульфонамид-содержащие связывающие системы для лекарственных конъюгатов | |
| RU2015119557A (ru) | Конъюгаты лекарственное вещество-белок | |
| JP2014527070A (ja) | 固形腫瘍を治療するためのfap活性化プロテアソーム阻害剤 | |
| CN118973617A (zh) | 缀合物、组合物及使用方法 | |
| CA2937600A1 (en) | Antibody-drug conjugates and immunotoxins | |
| JP2004529963A5 (cg-RX-API-DMAC7.html) | ||
| JP2016063817A5 (cg-RX-API-DMAC7.html) | ||
| JP2018509394A5 (cg-RX-API-DMAC7.html) |